BioProject

We performed gene and miRNA expression profiling in a series of 39 papillary thyroid carcinomas (PTCs) and 13 matched non-neoplastic thyroids derived from PTC patients with metastatic disease and submitted to radioiodine (RAI) treatment. More...

We performed gene and miRNA expression profiling in a series of 39 papillary thyroid carcinomas (PTCs) and 13 matched non-neoplastic thyroids derived from PTC patients with metastatic disease and submitted to radioiodine (RAI) treatment. Overall design: Gene and miRNA expression profiles were established by microarray analysis in a retrospective series of 52 snap-frozen thyroid samples including 35 tissues collected before RAI treatment (17 primary PTC tumors, 5 synchronous lymph node metastases (LNMs), and 13 matched non-neoplastic thyroids included as control) and 17 RAI-refractory LNMs collected as successive surgery following RAI treatment. Patients were stratified based on RAI uptake at the metastatic site and on RAI response in either avid or refractory, displaying disease remission or persistance, respectively, after RAI treatment. Gene profiles were established by Thermo Fisher Human Clariom S Assay, and the corresponding miRNA profiles were established by Agilent SurePrint Human miRNA microarrays. Tumor samples were also characterized for the most common driving mutations and gene fusions typical of PTC by a PTC-Mass Array platform (PTC-MA). Less...